Product image of Imatinib Viatris (Imatinib) supplied by GNH India

Imatinib Viatris

Active Ingredient:
Imatinib
Origin:
EU

Imatinib Viatris (Imatinib)

Imatinib, the active ingredient in Imatinib Viatris, is a tyrosine kinase inhibitor presented as an oral formulation for oral use. It treats chronic myeloid leukemia, Philadelphia chromosome‑positive acute lymphoblastic leukemia, gastrointestinal stromal tumor, systemic mastocytosis and dermatofibrosarcoma protuberans in adult patients.

GNH India supplies Imatinib Viatris as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Viatris Limited

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Imatinib acts on malignant cells driven by specific tyrosine‑kinase pathways, providing targeted therapy for several hematologic and solid tumours.

  • Chronic myeloid leukemia: suppresses BCR‑ABL‑driven proliferation and improves long‑term survival.
  • Philadelphia chromosome‑positive acute lymphoblastic leukemia: blocks leukemic blast growth and facilitates remission.
  • Gastrointestinal stromal tumor: inhibits c‑KIT and PDGFR signaling to reduce tumor size.
  • Systemic mastocytosis: curtails abnormal mast cell proliferation.
  • Dermatofibrosarcoma protuberans: interferes with PDGFR‑driven tumor growth.

How It Works

  • Imatinib selectively inhibits the tyrosine kinases BCR‑ABL, c‑KIT and PDGFR by binding to their ATP‑binding sites. This blocks downstream signaling cascades that drive uncontrolled cell division, survival and angiogenesis, leading to apoptosis of malignant cells and inhibition of tumor growth.

Side Effects

Adverse reactions may vary in frequency and severity.

Common Side Effects

  • Nausea: mild to moderate gastrointestinal upset.
  • Edema: peripheral swelling, often in the ankles.
  • Fatigue: generalized tiredness.
  • Muscle cramps: intermittent skeletal muscle discomfort.
  • Diarrhea: loose stools.
  • Rash: mild skin eruptions.

Serious or Rare Side Effects

  • Hepatotoxicity: elevated liver enzymes or liver injury.
  • Cardiotoxicity: decreased left‑ventricular ejection fraction.
  • Severe neutropenia: marked reduction in white blood cells.
  • Hemorrhage: bleeding tendencies.
  • Pulmonary arterial hypertension: increased pulmonary pressure.
  • Anaphylaxis: rare severe allergic reaction.

Precautions & Warnings

Patients should be monitored for organ function and potential toxicities before and during therapy.

  • Baseline labs: obtain complete blood count, liver and renal function tests.
  • Cardiac assessment: evaluate ejection fraction in patients with cardiac risk.
  • Drug interactions: review concomitant medications for CYP3A4 inhibitors/inducers.
  • Pregnancy and lactation: discuss risks with a qualified healthcare professional.
  • Storage: Store below 25°C: keep in the original container, protect from moisture and light.

Avoid Interactions

Imatinib may interact with several drug classes, altering efficacy or safety.

Major Interactions (Avoid)

  • Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase imatinib exposure.
  • Strong CYP3A4 inducers (e.g., rifampin): may reduce therapeutic levels.

Moderate Interactions (Monitor Closely)

  • Acid‑reducing agents (e.g., proton pump inhibitors): may affect absorption.
  • Anticoagulants (e.g., warfarin): may increase bleeding risk.
  • Vaccines (live attenuated): potential reduced efficacy.
  • Concomitant chemotherapy agents: may enhance myelosuppression.

Frequently Asked Questions

Imatinib Viatris is indicated for chronic myeloid leukemia, Philadelphia chromosome‑positive acute lymphoblastic leukemia, gastrointestinal stromal tumor, systemic mastocytosis and dermatofibrosarcoma protuberans. It targets specific tyrosine‑kinase pathways that drive these malignancies.

Imatinib binds to the ATP‑binding pocket of BCR‑ABL, c‑KIT and PDGFR tyrosine kinases, preventing their activation. This blocks downstream signaling that promotes cell proliferation and survival, leading to apoptosis of the malignant cells.

The prescribed dose of Imatinib Viatris is determined by the treating physician based on the specific indication, disease stage, patient weight, renal and hepatic function, and other clinical factors. Patients should follow the exact dosing instructions provided by their healthcare professional.

The safety of Imatinib during pregnancy or lactation has not been fully established. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss potential risks and benefits with their prescribing clinician before starting or continuing therapy.

To request Imatinib Viatris, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Imatinib was the first targeted BCR‑ABL inhibitor and remains a standard first‑line therapy for chronic myeloid leukemia. Newer agents such as dasatinib and nilotinib offer alternative potency and side‑effect profiles, but Imatinib’s long‑term safety data and broad regulatory approval make it a widely used option.

Imatinib Viatris should be stored at temperatures below 25 °C, in its original packaging, protected from moisture and direct light. Maintaining these conditions helps preserve the drug’s stability and potency throughout its shelf life.

Imatinib Viatris is taken orally, usually with a glass of water. It can be swallowed with or without food, but patients should follow any specific instructions from their prescriber regarding timing relative to meals.

Serious risks include hepatotoxicity, severe neutropenia, cardiac dysfunction (reduced left‑ventricular ejection fraction), pulmonary arterial hypertension and rare allergic reactions such as anaphylaxis. Patients should be monitored regularly for these adverse events.

Imatinib Viatris is contraindicated in patients with known hypersensitivity to imatinib or any of its excipients. Caution is advised for individuals with pre‑existing liver disease, cardiac impairment, or uncontrolled infections, and it should be avoided in patients for whom a safer alternative is available.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Imatinib

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT